Advertisement

Topics

BeFutur (Suisse) S.A. Company Profile

23:59 EDT 19th September 2017 | BioPortfolio

Considering the vast impact caused by the emergence of the biotechnologies, and eager to play a driving role in these evolutions, BeFutur Biotechnologies and its subsidiaries have set up an exclusive center in Europe, specialized in the culture of cells and tissues for therapeutic purposes. During the last 10 years, BeFutur has developed through own funding, its entire technology. This latter innovates on the market of biotechnologies while bringing a complete and safe response to the practice of the culture of cells and tissues for human clinical applications. To date the phase of research and development in the fields of cardiology, bio-cosmetic, aesthetic medicine and parodontology is finished, and BeFutur is fully operational, technically speaking, for the industrial phase and the marketing

Location

14, chemin des Clochettes
Geneva
1206
Switzerland

Contact

Phone: (41) 22 - 800 33 10
Fax: (41) 22 - 800 33 13
Email: info@befutur.com


News Articles [64 Associated News Articles listed on BioPortfolio]

Credit Suisse softens view on Teva, sees 21% downside risk; shares down 2% premarket

Bearish sentiment is still dogging Teva Pharmaceutical Industries . This morning, Credit Suisse downgraded the stock to Underperform and lowered its price target to $13 from $25.

Suisse BioAlps : le cru 2017 bien parti pour les biotechs

ÉDITION AUDIO accès libre – Après un cru 2016 exceptionnel, 2017 n’est pas mal non plus Claude Joris, directeur général du cluster BioAlps à Genève et grand connaisseur du secteur d...

Tuesday broker round-up

AA: Credit Suisse downgrades to Underperform with a target price of 175p. Ferrexpo: Credit Suisse reiterates Neutral with a target price of 250p.

Credit Suisse hebt Ziel für McDonalds - 'Outperform'

Die Schweizer Bank Credit Suisse hat das Kursziel für die Aktien der Restaurantkette McDonalds von 157 auf 165 US-Dollar angehoben und die Einstufung auf "Outperform" belassen. Dies schrieb Analys...

Credit Suisse belässt Microsoft auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für Microsoft auf "Outperform" mit einem Kursziel von 84 US-Dollar belassen. Dies geht aus einer am Freitag veröffentlichten Studie des Institut.....

Beteiligung von Buffet sorgte bei IBM-Aktie für Premiumbewertung! - Aktienanalyse

Zürich - IBM-Aktienanalyse von Analyst Kulbinder Garcha von der Credit Suisse: Kulbinder Garcha, Aktienanalyst bei der Credit Suisse, rechnet bei den Aktien von IBM Corp. (ISIN: US4592001014, WKN: .....

Credit Suisse senkt Pfizer auf 'Neutral' - Ziel 36 US-Dollar

Die Schweizer Bank Credit Suisse hat Pfizer von "Outperform" auf "Neutral" abgestuft und das Kursziel von 38 auf 36 US-Dollar gesenkt. Die kurzfristigen Möglichkeiten in der Medikamentenentwicklun...

Credit Suisse hebt Microsoft-Ziel auf 84 Dollar - 'Outperform'

Die Schweizer Bank Credit Suisse hat das Kursziel für Microsoft von 80 auf 84 US-Dollar angehoben und die Einstufung auf "Outperform" belassen. Dies geht aus einer am Montag veröffentlichten Studi.....

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Cellular radiance spf 30 [La Prairie, Inc.]

Cellular Radiance Emulsion SPF 30

Asacol [Cardinal Health]

Asacol (mesalamine)Delayed-Release Tablets

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

BeFutur (Suisse) S.A.

Considering the vast impact caused by the emergence of the biotechnologies, and eager to play a driving role in these evolutions, BeFutur Biotechnologies and its subsidiaries have set up an exclusive ...

Gen Suisse

Nil

Credit Suisse

We were one of the first investment banks to create specialized global industry groups, each dedicated to providing unmatched industry knowledge to its clients. Each industry is covered by senior prof...

Renaissance Capital Milestones

Renaissance Capital, founded in 1991 and headquartered in Greenwich, CT, is the leading provider of independent research and investment management services focused on newly public companies. The Firm ...

More Information about "BeFutur (Suisse) S.A." on BioPortfolio

We have published hundreds of BeFutur (Suisse) S.A. news stories on BioPortfolio along with dozens of BeFutur (Suisse) S.A. Clinical Trials and PubMed Articles about BeFutur (Suisse) S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BeFutur (Suisse) S.A. Companies in our database. You can also find out about relevant BeFutur (Suisse) S.A. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record